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ABSTRACT
Background: Growing antibiotic resistance demands the constant re-
assessment of antimicrobial efficacy, particularly in countries with wide anti-
biotic abuse, where higher resistance prevalence is often found. Knowledge of
resistance trends is particularly important when prescribing antibiotics empiri-
cally, as is usually the case for urinary tract infections (UTIs). Currently, in
Mexico City, ampicillin, cotrimoxazole (trimethoprim/sulfamethoxazole), and
ciprofloxacin are used as “first-line” antibiotic treatment for UTI.
Objective: The aim of this study was to analyze the resistance of bacterial
isolates to antibiotics, with a focus on first-line antibiotics, in Mexican pediatric
patients and sexually active or pregnant female outpatients.
Methods: In this multicenter susceptibility analysis, bacterial isolates from
urine samples collected from pediatric patients and sexually-active or pregnant
female outpatients presenting with acute, uncomplicated UTIs in Mexico City
from January 2006 through June 2006, were included in the study. Samples were
tested for susceptibility to 10 antibiotics by the disk-diffusion method.
Results: Four-hundred and seventeen bacterial isolates were derived from
sexually active or pregnant female outpatients (324 Escherichia coli) and pediatric
patients (93 Klebsiella pneumoniae). We found a high prevalence of resistance
towards the drugs used as “first-line” when treating UTIs: ampicillin, cotrimoxa-
zole, and ciprofloxacin (79%, 60%, and 24% resistance, respectively). Ninety-eight
percent of K pneumoniae isolates were resistant to ampicillin, whereas 66% of
the E coli isolates were resistant to cotrimoxazole. Resistance towards third-
generation cephalosporins was also high (6%–8% of E coli and 10%–28% of 
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K pneumoniae). This was possibly caused by chromosomal β-lactamases, as
30% of all isolates were also resistant to amoxicillin/clavulanate. In contrast,
98% of the E coli isolates and 84% of the K pneumoniae strains (96% of all iso-
lates) were found to be susceptible to nitrofurantoin, which has been in clinical
use for much longer than most other drugs in this study.
Conclusion: In these urine samples from laboratories in Mexico City, resis-
tance of K pneumoniae and E coli isolates to first-line treatment (ampicillin, cot-
rimoxazole, or ciprofloxacin) of UTI was high, whereas most E coli and K pneu-
moniae isolates were susceptible to nitrofurantoin and the fourth-generation
cephalosporin cefepime. (Curr Ther Res Clin Exp. 2007;68:120–126) Copyright ©
2007 Excerpta Medica, Inc.
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INTRODUCTION
The clinical efficacy of antibiotics declines with time.1 This decline, which is
specific to antimicrobial drugs, is caused by the emergence of bacterial vari-
eties that withstand or even thrive in the presence of formerly inhibitory
concentrations of such chemical agents. Resistance surveillance is the main
strategy to provide clues to guide the empirical use of antibiotics.2 Such sur-
veillance should be localized and updated as often as possible because re-
sistance trends can vary even between hospitals in the same city.2 Anti-
biotic resistance has been recognized as the consequence of antibiotic use and
abuse.3 As such, it is likely to be more prevalent in countries where antibiot-
ic usage is not strictly regulated. For instance, in Mexico antibiotics are avail-
able as “over-the-counter” drugs and self-prescription might account for up to
one-third of antibiotic sales at drugstores.4 Similar situations are common in
Latin American, Asian, and African countries.5 Therefore, resistance preva-
lence figures published from developed countries are not useful to guide
empirical therapy in developing countries. Currently, in Mexico City, ampi-
cillin, cotrimoxazole (trimethoprim/sulfamethoxazole), and ciprofloxacin are
used as “first-line” antibiotic treatment for urinary tract infections (UTIs).
The aim of this study was to analyze the susceptibility of bacterial isolates to
antibiotics, with a focus on first-line antibiotics, in Mexican pediatric patients
and sexually active or pregnant female outpatients.
MATERIAL AND METHODS
Bacterial Strains
In this multicenter susceptibility analysis, Klebsiella pneumoniae isolates
from positive routine urine cultures in male and female pediatric outpatients
and Escherichia coli isolates from sexually active or pregnant female outpatients,
all presenting with acute, uncomplicated UTIs, were included in this study
(these 2 populations were chosen because most uncomplicated UTIs in Mexico
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City are observed in them). Isolates were identified using standard biochemi-
cal techniques,6 and stored after isolation at –70°C in a glycerol-containing
medium until antibiotic susceptibility testing was performed. Only E coli and
K pneumoniae isolates were included, as those species were the only ones
occurring frequently enough to draw representative data.
Susceptibility Testing
Susceptibility was tested by the disk-diffusion method, using commercially-
available disks (Becton, Dickinson and Company, Franklin Lakes, New Jersey), 
following standard guidelines.7 The antibiotics tested included the following: 
β-lactams, ampicillin, amoxicillin/clavulanate, aztreonam, ceftazidime, ceftizoxime,
and cefepime; the aminoglycoside, netilmicin; the fluoroquinolone, ciprofloxacin;
cotrimoxazole (trimethoprim/sulfamethoxazole); and nitrofurantoin. Inhibitory
halo diameter was interpreted for each isolate to determine susceptibility. The
prevalence of “intermediate” strains was not reported because most of the drug
concentrations obtained in urine were high enough to inhibit these organisms,8
deeming them fully susceptible.
RESULTS
Three hundred twenty-four E coli isolates from sexually active or pregnant fe-
male outpatients and 93 K pneumoniae isolates from positive routine urine
cultures in pediatric outpatients, all presenting with acute, uncomplicated UTIs
in Mexico City from January 2006 through June 2006, were included in this
study. Resistance prevalence for each species is shown in the table.
We found a high prevalence of resistance towards the drugs used as “first-
line” against UTIs: ampicillin (78%), cotrimoxazole (60%), and ciprofloxacin
(24%). Almost all (98%) K pneumoniae isolates were resistant to ampicillin,
whereas 66% of the E coli isolates were resistant to cotrimoxazole. Resistance
towards third-generation cephalosporins was also high (6%–13% of all isolates).
This was possibly caused by chromosomal β-lactamases, as 30% of all isolates
were also resistant to amoxicillin/clavulanate. In contrast, 98% of E coli isolates
and 84% of K pneumoniae strains (96% of all isolates) were found to be suscep-
tible to nitrofurantoin, which has been in clinical use for much longer than most
other drugs.
DISCUSSION
Susceptibility of uropathogenic bacteria in developed countries, although cer-
tainly growing, is low enough to still consider the use of cotrimoxazole, amino-
penicillins, or fluoroquinolones as drugs of first choice. A 2003 study9 of anti-
microbial susceptibility of pathogens from uncomplicated UTIs that included
252 health centers from 16 European countries and Canada, found that among
2478 E coli isolates, 30% were resistant to ampicillin, 14% to cotrimoxazole, and
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2% to ciprofloxacin. Studies in the United States have found that the resistance
prevalence was roughly the same.10,11
Our results include resistance prevalences that are 2- to 10-fold higher for these
antibiotics: 73% of the E coli isolates in our study were resistant to ampicillin, 66%
to cotrimoxazole, and 29% to ciprofloxacin. This increase in resistance has been
observed for some time in Mexico and other Latin American countries. In a Mexican
survey from 1997,12 60% of uropathogenic E coli were found to be resistant to ampi-
cillin, 55% to cotrimoxazole, and 32% to norfloxacin. In Argentina, between 1996 and
1998,12 44% to 76% of uropathogenic E coli were found to be resistant to ampicillin,
27% to 46% to cotrimoxazole, and 2% to 26% to ciprofloxacin.
These differences might be attributed to a number of reasons: (1) medical
abuse of antibiotics, as several studies have shown that higher rates of anti-
biotic prescription are linked to higher resistance prevalence3; (2) self-prescription,
which may account for up to 30% of antibiotics sold at drugstores in Mexico City4;
drugs more often used by self-prescription include aminopenicillins and sulfon-
amides (the 2 drug classes with higher resistance prevalence in this study); and
self-prescribed treatments are often shorter than the clinically-accepted length,13
which is more likely to select resistant organisms; and (3) abundance of generic
drugs without adequate quality control, which might result in suboptimal plasma
and/or tissue concentrations of drugs because of deficient pharmaceutical formu-
lations. However, the lack of accurate data on antibiotic usage prevents the afore-
mentioned from being more than educated guesses.
Table. Resistance prevalence in isolates of Escherichia coli collected from sexually-
active or pregnant female outpatients and Klebsiella pneumoniae collected
from pediatric patients in Mexico City suffering acute, uncomplicated, urinary
tract infections. Values are no. (%).
Resistant Strains
E coli K pneumoniae Total 
Antibiotic (n = 324) (n = 93) (N = 417)
Ampicillin 236 (73) 91 (98) 327 (78)
Cotrimoxazole* 213 (66) 36 (39) 249 (60)
AMC 74 (23) 52 (56) 126 (30)
Ciprofloxacin 92 (28) 7 (8) 99 (24)
Aztreonam 34 (10) 23 (25) 57 (14)
Ceftazidime 27 (8) 26 (28) 53 (13)
Netilmicin 17 (5) 24 (26) 41 (10)
Ceftizoxime 18 (6) 9 (10) 27 (6)
Nitrofurantoin 8 (2) 15 (16) 23 (6)
Cefepime 14 (4) 0 14 (3)
AMC = amoxicillin/clavulanate.
*Trimethoprim/sulfamethoxazole.
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Some further information can be inferred from the results. The high preva-
lence of resistance towards amoxicillin/clavulanate in this study (23% of 
E coli strains, 56% of K pneumoniae strains) suggests that the over-expression
of chromosomal β-lactamase AmpC is an important component of overall
resistance to β-lactams. The high prevalence of fluoroquinolone resistance
(represented in this study by ciprofloxacin), is considered to be caused pri-
marily by mutations on chromosomal genes.14 Combined, these data suggest
that the uropathogenic bacteria observed are not acquiring resistance
through horizontal gene transfer, but by isolated selective events. Because
the urinary tract is mainly sterile and infections located there are mostly
caused by a single type of pathogenic organism, perhaps this tract is an iso-
lated environment where gene exchange cannot occur often. However, it is
also possible that conditions in the urinary tract convey invading bacteria
towards a hyper-mutable state, as reported for other kinds of infectious
processes.15
One of the most effective antimicrobial agents amongst the ones tested
here was nitrofurantoin; only less effective than the fourth-generation
cephalosporin cefepime in overall results and the best agent observed ver-
sus E coli. This was particularly interesting as the drug has been available in
crystalline form since 1953,16 well before all of the other drugs tested in this
study. Because of its pleiotropic mechanism of action, resistance to nitrofu-
rantoin has been slow to occur.16 And, despite resistance being seldom found
in developed countries (1.2% in Europe,9 0.5% in the United States10), this
drug is not usually considered as a first choice. Among neonates, where UTIs
are regarded as a potential sign of bacteremia, drugs other than nitrofuran-
toin are preferred; but, when the infection is presumably localized, this drug
may be a valid option. Nitrofurantoin is a well tolerated drug even for pedi-
atric and extended use16; the in vitro results shown here indicate that nitro-
furantoin might be an alternative in countries where other antibiotics face a
high prevalence of resistance.
Based on the results of this study, we suggest there is a need for local sur-
veillance to guide the empirical prescription of antibiotics against UTIs, and
how drugs such as nitrofurantoin, that have been used clinically for a long
time, might be considered as important options in the handling of infectious
diseases caused by bacteria resistant to newer drugs.
CONCLUSION
In these urine samples from laboratories in Mexico City, resistance of K pneu-
moniae and E coli isolates to first-line treatment (ampicillin, cotrimoxazole,
or ciprofloxacin) of UTI was high, whereas most E coli and K pneumoniae iso-
lates were susceptible to nitrofurantoin and the fourth-generation cephalo-
sporin cefepime.
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